Mark Alexander Nelson
CIK: 0001352919
Transaction Breakdown
Open Market Buys (P)0
High conviction signal
Open Market Sales (S)0
Position reduction
Option Exercises (M)0
Derivative conversions
Awards (A)0
Compensation grants
Other (G, F, J, C, D, …)0
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
TLX
Telix Pharmaceuticals Ltd
Director
Discretionary Trading P&L
Holdings
Transaction History (0 total)
1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024.
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| 1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024. | ||||||
0-0 of 0 transactions
About Nelson Mark Alexander
Nelson Mark Alexander (SEC CIK 0001352919) files insider reports with the SEC as Director of Telix Pharmaceuticals Ltd (TLX).
Signal8 holds 1 ownership filing by Nelson Mark Alexander, a Form 3, filed on Apr 1, 2026. A Form 3 is an initial statement of ownership: it reports holdings, not trades, so no Form 4 or Form 5 transactions are on record since Sep 2024.
The business address on Nelson Mark Alexander's filings is in NORTH MELBOURNE.
Other insiders filing for Telix Pharmaceuticals Ltd (TLX)
- Smith Darren Charlton, Group Chief Financial Officer
- GILL DAVID N, Director
- Jellison William R, Director
- Rivas Maria, Director
- Behrenbruch Christian, MD & Group CEO
- Cade David Norman, Group Chief Medical Officer